• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Arms Pharmaceutical touts oral spray for upper respiratory tract infections

February 8, 2017 By Sarah Faulkner

Arms PharmaceuticalArms Pharmaceutical touts oral spray for upper respiratory tract infections touted data from a proof-of-concept clinical trial evaluating its oral spray formulation, Arms-I, for upper respiratory tract infections.

The placebo-controlled trial demonstrated that the oral spray formulation is safe, well-tolerated and reduced influenza symptoms, according to the Cleveland-based pharmaceutical company.

“The results confirm that our Arms-I technology has tremendous potential to lead the next generation of drugs in not only the prevention of many upper respiratory infectious diseases, such as influenza, rhinovirus and respiratory syncytial virus, but in the treatment of them as well,” chief scientific officer Mahmoud Ghannoum said in prepared remarks.

The company’s Arms-I formulation is composed of a broad-spectrum antimicrobial, centylpyridinium chloride, and glycerin and xantham gum, which forms a barrier on the host mucosa. The barrier prevents viral contact and invasion into the host cells.

The FDA has approved the company’s Investigational New Drug Application for a pharmacokinetic trial of its Arms-I drug, Arms Pharmaceutical reported.

“It is an exciting time for the company as we actively begin discussions with potential strategic partners to bring Arms-I to market, a drug with the potential to help millions of people prevent influenza without the worries of side effects or viral resistance,” CEO Afif Ghannoum added.

Filed Under: Clinical Trials, Featured, Respiratory, Wall Street Beat Tagged With: Arms Pharmaceutical

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS